# Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Source: https://onco.cc/trials/nct07314294/  
OnCo record `nct07314294` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of EMB-01 1600 mg administered once weekly throughout the study in colorectal cancer, run by Shanghai EpimAb Biotherapeutics Co., Ltd., now recruiting.

## Summary

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT07314294 by Shanghai EpimAb Biotherapeutics Co., Ltd., with 54 participants planned, started 2025-12-18 and due to reach its primary completion in 2027-12-30. Interventions recorded: EMB-01 1600 mg administered once weekly throughout the study and EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07314294
- Phase: 2
- Setting: A Randomized, Open-label, Phase II Study of EMB-01 in Patients With Recurrent/Metastatic Colorectal Cancer
- Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT07314294: https://clinicaltrials.gov/study/NCT07314294

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct07314294.json